{"id":"powder-bont-a-botox-vistabel","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Injection site pain or bruising"},{"rate":"1–3","effect":"Eyelid ptosis"},{"rate":"1–2","effect":"Brow ptosis"},{"rate":"1–5","effect":"Facial asymmetry"},{"rate":"1–3","effect":"Muscle weakness"}]},"_chembl":{"chemblId":"CHEMBL2109052","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BoNT-A is a neurotoxin that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release at the presynaptic terminal. This prevents neuromuscular transmission, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and muscle function returns.","oneSentence":"Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:37:02.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe glabellar lines (frown lines) in adults"},{"name":"Moderate to severe lateral canthal lines (crow's feet) in adults"},{"name":"Forehead lines in adults"},{"name":"Cervical dystonia"},{"name":"Chronic migraine"},{"name":"Hyperhidrosis (excessive sweating)"},{"name":"Spasticity"}]},"trialDetails":[{"nctId":"NCT05277337","phase":"PHASE4","title":"Study Comparing Treatment With Alluzience vs Reconstituted Toxin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-02-04","conditions":"Glabellar Frown Lines","enrollment":150},{"nctId":"NCT00777803","phase":"PHASE3","title":"NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-11","conditions":"Glabellar Frown Lines","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"powder BoNT-A (BOTOX/Vistabel)","genericName":"powder BoNT-A (BOTOX/Vistabel)","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Biologic","firstApprovalDate":"","aiSummary":"Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Moderate to severe glabellar lines (frown lines) in adults, Moderate to severe lateral canthal lines (crow's feet) in adults, Forehead lines in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}